Status:
COMPLETED
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy
Lead Sponsor:
ASST Fatebenefratelli Sacco
Collaborating Sponsors:
ALK-Abelló A/S
Conditions:
Pollen Allergy
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
The dose and the mode of administration of sublingual therapy remain open questions to determine the efficacy and safety of this desensitization therapy, the main purpose of this study is to evaluate ...
Detailed Description
Version 1 16/02/2011 The allergen-specific immunotherapy represents an important therapeutic option for the treatment of allergic respiratory diseases. Its clinical efficacy is well demonstrated, alth...
Eligibility Criteria
Inclusion
- Adults aged 18-55 years
- Known allergy to ragweed pollen
- No immunotherapy or in progress prior to enrollment
- Symptoms of rhino / conjunctivitis with or without asthma
Exclusion
- Allergic to perennial allergens (moulds, mites and animal when exposed to the animal)
- Patients with chronic diseases (infectious, autoimmune cancer, heart or kidney)
- Are pregnant
- Chronic drug treatment with steroids and / or immunosuppressive
- Oral disease
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01500642
Start Date
June 1 2011
End Date
September 1 2011
Last Update
January 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Luigi Sacco Hospital
Milan, Italy, 20157